Intravenous Tissue Plasminogen Activator in Stroke Mimics

In-hospital stroke treated with intravenous tissue plasminogen activator.

BACKGROUND AND PURPOSE In-hospital strokes (IHSs) are potential candidates for thrombolysis. We analyzed the treatment procedures, safety, and efficacy of intravenous tissue plasminogen activator (IV-tPA) in IHSs compared with out-of-hospital strokes (OHSs). METHODS This study was based on a multicenter prospective registry of patients treated with IV-tPA divided into IHSs and OHSs. We record...

The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...

Defining intravenous recombinant tissue plasminogen activator failure.

Administering Intravenous Alteplase (Tissue Plasminogen Activator [tPA])

Step 1: Eligibility-The eligibility criteria for patients with acute ischemic stroke within 3 hours of symptom onset include: • An adult (> 18 years of age) • Exclusion of intrancranial hemorrhage by an imaging technique sensitive for the presence of hemorrhage • Arrives at the emergency department in time to be treated within 3 hours of symptom onset • The recommended dose of IV tPA is 0.9 mg/...

Tissue-plasminogen activator for acute ischaemic stroke.

BACKGROUND Thrombolytic therapy for acute ischemic stroke has been approached cautiously because there were high rates of intracerebral hemorrhage in early clinical trials. We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was beneficial when treatment was begun within t...